scholarly journals High-Dose Vitamin D Does Not Prevent Postoperative Recurrence of Crohn’s Disease in a Randomized Placebo-Controlled Trial

2020 ◽  
Author(s):  
Jessica R. de Bruyn ◽  
Peter Bossuyt ◽  
Marc Ferrante ◽  
Rachel L. West ◽  
Gerard Dijkstra ◽  
...  
Keyword(s):  
Vitamin D ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Controlled Trial ◽  
Postoperative Recurrence ◽  
High Dose ◽  
High Dose Vitamin

scholarly journals 144 – Postoperative Endoscopic and Clinical Recurrence After Ileocolonic Resection in Patients with Crohn's Disease Cannot Be Prevented with High Dose Vitamin D

2019 ◽  
Vol 156 (6) ◽  
pp. S-33
Author(s):  
Jessica de Bruyn ◽  
Peter Bossuyt ◽  
Marc Ferrante ◽  
Rachel West ◽  
Gerard Dijkstra ◽  
...  
Keyword(s):  
Vitamin D ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
High Dose ◽  
Clinical Recurrence ◽  
Ileocolonic Resection ◽  
High Dose Vitamin

Sunshine is an Important Determinant of Vitamin D Status Even Among High-dose Supplement Users: Secondary Analysis of a Randomized Controlled Trial in Crohn's Disease Patients

2019 ◽  
Vol 95 (4) ◽  
pp. 1060-1067 ◽  
Author(s):  
Fiona O'Sullivan ◽  
Tara Raftery ◽  
Michiel van Weele ◽  
Jos van Geffen ◽  
Deirdre McNamara ◽  
...  
Keyword(s):  
Vitamin D ◽  
Randomized Controlled Trial ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Important Determinant ◽  
Controlled Trial ◽  
Secondary Analysis ◽  
High Dose ◽  
Vitamin D Status ◽  
Randomized Controlled

scholarly journals Seven Weeks of High-Dose Vitamin D Treatment Reduces the Need for Infliximab Dose-Escalation and Decreases Inflammatory Markers in Crohn’s Disease during One-Year Follow-Up

Nutrients ◽  
2021 ◽  
Vol 13 (4) ◽  
pp. 1083
Author(s):  
Mia Bendix ◽  
Anders Dige ◽  
Søren Peter Jørgensen ◽  
Jens Frederik Dahlerup ◽  
Bo Martin Bibby ◽  
...  
Keyword(s):  
Vitamin D ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Dose Escalation ◽  
Inflammatory Markers ◽  
High Dose ◽  
One Year ◽  
Group D ◽  
High Dose Vitamin

Background: Seven weeks of high-dose vitamin D treatment decreases intestinal IL17A and IFN-γ mRNA expression in active Crohn’s disease (CD). In this follow-up study, we investigated whether seven-week vitamin D treatment affected the infliximab response in the following 45 weeks compared to placebo. Methods: CD patients (n = 40) were initially randomised into four groups: infliximab + vitamin-D; infliximab + placebo-vitamin-D; placebo-infliximab + vitamin-D; and placebo-infliximab + placebo-vitamin-D. Infliximab (5 mg/kg) or placebo-infliximab was administered at weeks 0, 2 and 6. Vitamin D (5 mg bolus followed by 0.5 mg/day for 7 weeks) or placebo-vitamin D was handed out. After the 7-week vitamin D period, all patients received infliximab during follow-up. Results are reported for Group D+ (infliximab + vitamin-D and placebo-infliximab + vitamin-D) and Group D- (infliximab + placebo-vitamin-D and placebo-infliximab + placebo-vitamin-D). Results: Group D- patients had greater needs for infliximab dose escalation during follow-up compared to group D+ (p = 0.05). Group D+ had lower median calprotectin levels week 15 (p = 0.02) and week 23 (p = 0.04) compared to group D-. Throughout follow-up, group D+ had 2.2 times (95% CI: 1.1–4.3) (p = 0.02) lower median CRP levels compared with group D-. Conclusions: Seven weeks high-dose vitamin D treatment reduces the need for later infliximab dose-escalation and reduces inflammatory markers. EudraCT no. 2013-000971-34.

scholarly journals Decrease in Mucosal IL17A, IFNγ and IL10 Expressions in Active Crohn’s Disease Patients Treated with High-Dose Vitamin D Alone or Combined with Infliximab

Nutrients ◽  
2020 ◽  
Vol 12 (12) ◽  
pp. 3699
Author(s):  
Mia Bendix ◽  
Anders Dige ◽  
Søren Peter Jørgensen ◽  
Jens Frederik Dahlerup ◽  
Bo Martin Bibby ◽  
...  
Keyword(s):  
Vitamin D ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Disease Activity ◽  
Fecal Calprotectin ◽  
Cytokine Expression ◽  
High Dose ◽  
Treatment Groups ◽  
Reactive Protein ◽  
High Dose Vitamin

Background: Vitamin D treatment may reduce Crohn’s disease (CD) activity by modulating the mucosal immune function. We investigated if high-dose vitamin D +/− infliximab modulated the mucosal cytokine expression in active CD. Methods: Forty CD patients were randomized into: infliximab + vitamin D; infliximab + placebo-vitamin D; placebo-infliximab + vitamin D or placebo-infliximab + placebo-vitamin D. Infliximab (5 mg/kg) and placebo-infliximab were administered at weeks 0, 2 and 6. Oral vitamin D was administered as bolus 200,000 international units (IU) per week 0 followed by 20,000 IU/day for 7 weeks or placebo. Endoscopy with biopsies was performed at weeks 0 and 7 where endoscopic activity was measured and mucosal mRNA cytokine expression was examined. C-reactive protein (CRP), fecal calprotectin and Harvey-Bradshaw Index (HBI) were measured at weeks 0, 2 and 6. Results: High-dose vitamin D treatment alone and combined with infliximab decreased the IL17A, IFNγ and IL10 expression. High-dose vitamin D alone did not significantly decrease the disease activity, CRP or calprotectin. Combined infliximab and vitamin D treatment was not clinically significantly superior to monotherapy with infliximab. Conclusions: High-dose vitamin D as monotherapy and combined with infliximab decreases IL17A, IFNγ and IL-10 expression in mucosa within treatment groups. This did not induce a statistically significant decreased disease activity. EudraCT no.2013-000971-34.

scholarly journals Single High-Dose Vitamin D Supplementation as an Approach for Reducing Ultramarathon-Induced Inflammation: A Double-Blind Randomized Controlled Trial

Nutrients ◽  
2021 ◽  
Vol 13 (4) ◽  
pp. 1280
Author(s):  
Jan Mieszkowski ◽  
Andżelika Borkowska ◽  
Błażej Stankiewicz ◽  
Andrzej Kochanowicz ◽  
Bartłomiej Niespodziński ◽  
...  
Keyword(s):  
Vitamin D ◽  
Inflammatory Marker ◽  
Controlled Trial ◽  
Vitamin D Supplementation ◽  
Oncostatin M ◽  
Control Group ◽  
High Dose ◽  
Double Blind ◽  
Single High Dose ◽  
High Dose Vitamin

Purpose: A growing number of studies indicate the importance of vitamin D supplementation for sports performance. However, the effects of a single high-dose vitamin D supplementation on ultramarathon-induced inflammation have not been investigated. We here analyzed the effect of a single high-dose vitamin D supplementation on the inflammatory marker levels in ultramarathon runners after an ultramarathon run (maximal run 240 km). Methods: In the study, 35 runners (amateurs) were assigned into two groups: single high-dose vitamin D supplementation group, administered vitamin D (150,000 IU) in vegetable oil 24 h before the start of the run (n = 16); and placebo group (n = 19). Blood was collected for analysis 24 h before, immediately after, and 24 h after the run. Results: Serum 25(OH)D levels were significantly increased after the ultramarathon in both groups. The increase was greater in the vitamin D group than in the control group. Based on post-hoc and other analyses, the increase in interleukin 6 and 10, and resistin levels immediately after the run was significantly higher in runners in the control group than that in those in the supplementation group. Leptin, oncostatin M, and metalloproteinase tissue inhibitor levels were significantly decreased in both groups after the run, regardless of the supplementation. Conclusions: Ultramarathon significantly increases the serum 25(OH)D levels. Attenuation of changes in interleukin levels upon vitamin D supplementation confirmed that vitamin D has anti-inflammatory effect on exercise-induced inflammation.

The Correlation between Vitamin D Levels and the Risk of Postoperative Recurrence in Crohn’s Disease

Digestion ◽  
2021 ◽  
pp. 1-9
Author(s):  
Akihiro Yamada ◽  
Yuga Komaki ◽  
Fukiko Komaki ◽  
Haider Haider ◽  
Dejan Micic ◽  
...  
Keyword(s):  
Vitamin D ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Postoperative Recurrence ◽  
Recurrence Rates ◽  
Reactive Protein ◽  
Endoscopic Recurrence ◽  
Vitamin D Levels ◽  
Endoscopic Remission ◽  
The University

<b><i>Background and Aims:</i></b> Vitamin D deficiency has been associated with disease activity in Crohn’s disease (CD). We assessed whether there is a correlation between vitamin D levels and the risk of postoperative recurrence in CD. <b><i>Methods:</i></b> CD patients who underwent surgery were identified from a prospectively maintained database at the University of Chicago. The primary endpoint was the correlation of serum 25-hydroxy vitamin D levels measured at 6–12 months after surgery and the proportion of patients in endoscopic remission, defined as a simple endoscopic score for CD of 0. Clinical, biological (C-reactive protein), and histologic recurrences were also studied. <b><i>Results:</i></b> Among a total of 89 patients, 17, 46, and 26 patients had vitamin D levels of &#x3c;15, 15–30, and &#x3e;30 ng/mL, respectively. Patients with higher vitamin D levels were significantly more likely to be in endoscopic remission compared to those with lower levels (23, 42, and 67% in ascending tertile order; <i>p</i> = 0.028). On multivariate analysis, vitamin D &#x3e;30 ng/mL (odds ratio [OR] 0.22, 95% confidence interval [CI] 0.07–0.66, <i>p</i> = 0.006) and anti-tumor necrosis factor agent treatment (OR 0.25, 95% CI 0.08–0.83, <i>p</i> = 0.01) were associated with reduced risk of endoscopic recurrence. Rates of clinical, biological, and histologic remission trended to be higher in patients with higher vitamin D levels (<i>p</i> = 0.17, 0.55, 0.062, respectively). <b><i>Conclusion:</i></b> In the present study, higher vitamin D level was associated with lower risk of postoperative endoscopic CD recurrence. Further, studies are warranted to assess the role of vitamin D in postoperative CD recurrence.

scholarly journals Monthly high-dose vitamin D supplementation does not increase kidney stone risk or serum calcium: results from a randomized controlled trial

2019 ◽  
Vol 109 (6) ◽  
pp. 1578-1587 ◽  
Author(s):  
Zarintaj Malihi ◽  
Carlene M M Lawes ◽  
Zhenqiang Wu ◽  
Ying Huang ◽  
Debbie Waayer ◽  
...  
Keyword(s):  
Vitamin D ◽  
Randomized Controlled Trial ◽  
Serum Calcium ◽  
Kidney Stone ◽  
Controlled Trial ◽  
Vitamin D Supplementation ◽  
High Dose ◽  
Randomized Controlled ◽  
High Dose Vitamin

scholarly journals Effect of monthly high-dose vitamin D on bone density in community-dwelling older adults substudy of a randomized controlled trial

2017 ◽  
Vol 282 (5) ◽  
pp. 452-460 ◽  
Author(s):  
I. R. Reid ◽  
A. M. Horne ◽  
B. Mihov ◽  
G. D. Gamble ◽  
F. Al-Abuwsi ◽  
...  
Keyword(s):  
Older Adults ◽  
Vitamin D ◽  
Randomized Controlled Trial ◽  
Bone Density ◽  
Controlled Trial ◽  
Community Dwelling ◽  
High Dose ◽  
Randomized Controlled ◽  
Community Dwelling Older Adults ◽  
High Dose Vitamin

Sa1779 Vitamin D Modulates T Cell-Mediated Immunity: Results From a Randomized Controlled Trial of Low-Dose and High-Dose Vitamin D3

2014 ◽  
Vol 146 (5) ◽  
pp. S-294 ◽  
Author(s):  
Gauree G. Konijeti ◽  
Matthew R. Boylan ◽  
Yanna Song ◽  
Pankaj Arora ◽  
Frank E. Harrell ◽  
...  
Keyword(s):  
Vitamin D ◽  
Randomized Controlled Trial ◽  
T Cell ◽  
Vitamin D3 ◽  
Low Dose ◽  
Controlled Trial ◽  
High Dose ◽  
Cell Mediated Immunity ◽  
Randomized Controlled ◽  
High Dose Vitamin
Sign in / Sign up

Export Citation Format

Share Document